Efficacy

Alunbrig (brigatinib) Efficacy in Lung Cancer

Alunbrig (brigatinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. It is particularly effective in patients with NSCLC that is anaplastic lymphoma kinase-positive (ALK+), which is a subgroup of lung cancer characterized by the presence of an abnormal ALK gene. Clinical trials have demonstrated that brigatinib is highly effective in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor. In these studies, brigatinib has shown a significant improvement in progression-free survival compared to chemotherapy and has been associated with high response rates in patients with ALK+ NSCLC.

Moreover, brigatinib has proven to be effective in treating patients with brain metastases, which is a common complication of advanced NSCLC. The intracranial response rate and duration of response in patients with measurable brain metastases have been particularly encouraging, making brigatinib a valuable option for this difficult-to-treat population. The efficacy of brigatinib after crizotinib failure suggests that it can be an important second-line treatment for patients with ALK+ NSCLC.

Exkivity (mobocertinib) Efficacy in Lung Cancer

Exkivity (mobocertinib) is another targeted therapy that has shown efficacy in the treatment of NSCLC, specifically in patients with tumors that have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are associated with resistance to many of the currently available EGFR inhibitors. As an oral therapy, mobocertinib has been granted accelerated approval based on the response rate and duration of response observed in clinical trials. Patients with EGFR exon 20 insertion-positive NSCLC who have been previously treated with platinum-based chemotherapy have experienced significant tumor shrinkage and prolonged periods of disease control with mobocertinib treatment.

The clinical development of mobocertinib is ongoing, with studies aiming to confirm the clinical benefit in a larger cohort of patients. However, the current data suggest that mobocertinib provides a much-needed treatment option for patients with EGFR exon 20 insertion-positive NSCLC, particularly after the failure of first-line chemotherapy. The drug's ability to target this specific mutation allows for a more personalized approach to lung cancer treatment, which can lead to better outcomes for patients with this genetic profile.